Comment from Anat Loewenstein

Summary: Dr. Anat Loewenstein, Head of Retina at Tel Aviv Medical Center, supports the Haystack Project’s Petition for Rulemaking. He argues that the FDA should adopt a framework that considers disease-specific factors—such as heterogeneity and progression rates—when evaluating whether clinical investigations in rare diseases are "adequate and well-controlled."